OnabotulinumtoxinA is now an important tool for managing pediatric neurogenic lower urinary tract dysfunction
Initial urologic management of pediatric neurogenic lower urinary tract dysfunction (NLUTD) includes clean intermittent catheterization (CIC) regimen and use of anticholinergic or beta3 agonist medications. Historically, NLUTD that did not respond to these initial management strategies received open...
Saved in:
Main Authors: | Brendan T. Frainey (Author), Douglass B. Clayton (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2024-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmacological correction of neurogenic lower urinary tract dysfunction in children
by: T.P. Borysova, et al.
Published: (2020) -
OnabotulinumtoxinA for chronic migraine: a critical appraisal
by: Gooriah R, et al.
Published: (2015) -
Treatment of Non-neurogenic Overactive Bladder with OnabotulinumtoxinA: Systematic Review and Meta-analysis of Prospective, Randomized, Placebo-controlled Clinical Trials
by: Raquel Martins Arruda, et al.
Published: (2018) -
New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA
by: Andersson KE
Published: (2013) -
A Preclinical Study Comparing the Activity and Potency of OnabotulinumtoxinA and PrabotulinumtoxinA
by: Rupp DC, et al.
Published: (2023)